Rhett M. Schiffman, M.D.
Chief Medical Officer & Executive Vice President, Research & Development
Dr. Rhett Schiffman is Senior Vice President of Development and Chief Medical Officer at Envisia.
Previously, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program through phase 1/2 clinical trials.
Prior to Neurotech, he was Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan where he played a key role in the global development and approval of many successful products including Restasis®, Combigan®, Lumigan®, Acuvail®/Acular®.
Zymaxid®/Zymar®, as well as Lumigan® and Ganfort® unit dose products.
Dr. Schiffman received his B.S. in Bioengineering from Columbia University and his M.D. from the University of Juarez, Mexico.
He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration.
He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital in Michigan and is Board Certified in both specialties and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health.
He has served on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine where he sees patients and teaches residents.